Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 26:13:81-89.
doi: 10.2147/IPRP.S458827. eCollection 2024.

Warfarin and Polypharmacy Challenges in Sudan: Drug Interactions in Patient Cohort

Ahmed A A Omer  1 , Abdal Mahmoud Elsiddig  2 , Imad M Taj  1
Affiliations

Warfarin and Polypharmacy Challenges in Sudan: Drug Interactions in Patient Cohort

Ahmed A A Omer et al. Integr Pharm Res Pract. .

Abstract

Purpose: Warfarin plays an important role in anticoagulation therapy despite the availability of the newest oral anticoagulants, and achieving optimal anticoagulation is challenging due to its narrow therapeutic range and variable dose. This study aimed to highlight polypharmacy and drug interactions in patients receiving warfarin therapy at Medani Heart Centre, Sudan.

Methods: This retrospective hospital-based study was conducted from May 2017 to October 2018. Each concurrent medication prescribed for 104 patients was collected and checked for drug-drug interactions using Medscape Reference-Drug Interaction Checker. The data were analysed by using SPSS 20, and descriptive statistics were used.

Results: The results revealed that 95.2% of patients had more than three medications in their profile, (3-5), (6-9) and more than 10 medications were prescribed for 40.4%, 44.2% and 10.6% of patients, respectively. A total of 93.3% of patients had drug-drug interactions, as follows: (1-5), (6-10), (11-15), (16-20) and more than 20 drug-drug interactions were found in 31.7%, 32.7%, 19.2%, 5.8% and 3.8% of patients, respectively. A total of 178 warfarin-drug interactions were identified in 88.5% of the patients. The INR ranged between 2 and 2.99 in 13.4% of patients, and INR values below 2 and above 5 were found in 44.2% and 21.2% of patients, respectively. Analgesics (n=54; 30.3%), cardiovascular drugs (n=51; 28.6%), and anticoagulants (n=46; 25.8%) were the most common drug classes that interact with warfarin. Significant and serious types of interactions with warfarin were found in 51% and 37.5% of patients, respectively.

Conclusion: This study highlights the complexity of managing warfarin therapy amid prevalent polypharmacy. A substantial majority of patients experienced multiple drug interactions. The identification of significant and serious interactions emphasizes the need for vigilant management strategies, including improved communication among healthcare professionals and targeted education for both providers and patients, to enhance the safety and efficacy of warfarin therapy.

Keywords: INR; drug-drug interaction; patient; poly pharmacy; warfarin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Types of interactions according to the Medscape Drug Interaction Checker. The interactions with warfarin were classified as significant interactions, serious interactions, or no warfarin drug interactions.
See this image and copyright information in PMC

References

    1. Lee MTM, Klein TE. Pharmacogenetics of warfarin: challenges and opportunities. J Hum Genet. 2013;58(6):334–338. doi:10.1038/jhg.2013.40 - DOI - PMC - PubMed
    1. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026 - DOI - PubMed
    1. Wang -Z-Z, Du X, Wang W, et al. Long-term persistence of newly initiated warfarin therapy in Chinese patients with nonvalvular atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2016;9(4):380–387. doi:10.1161/CIRCOUTCOMES.115.002337 - DOI - PubMed
    1. Becattini C, Agnelli G. Treatment of venous thromboembolism with new anticoagulant agents. J Am Coll Cardiol. 2016;67(16):1941–1955. doi:10.1016/j.jacc.2016.01.072 - DOI - PubMed
    1. Leite PM, Martins MAP, Das Graças Carvalho M, Castilho RO. Mechanisms and interactions in concomitant use of herbs and warfarin therapy: an updated review. Biomed Pharmacother. 2021;143:112103. doi:10.1016/j.biopha.2021.112103 - DOI - PubMed